翰宇药业2025上半年扭亏为盈 国际业务收入占比超七成

Group 1 - The core viewpoint of the news is that Shenzhen Hanyu Pharmaceutical Co., Ltd. has reported significant growth in its financial performance for the first half of 2025, driven by international business expansion and improved operational efficiency [1] - The company achieved a revenue of 549 million yuan, representing a year-on-year increase of 114.86%, and a net profit of 145 million yuan, marking a turnaround from losses [1] - The operating cash flow reached 157 million yuan, up 376.42% year-on-year, indicating strong cash generation capabilities [1] Group 2 - The international business revenue amounted to 425 million yuan, increasing its share of total revenue from 55.10% in the same period of 2024 to 77.40% [1] - The company has expanded its international business coverage to over 90 countries and regions, including North America, South America, Europe, Asia, and the Middle East [1] - The company has effectively controlled its expenses, with sales expenses down 10.08%, management expenses down 5.15%, and financial expenses down 10.06%, contributing to the rapid growth of net profit [1] Group 3 - In terms of innovation, the company is focusing on the development of innovative weight-loss drugs using AI drug screening, targeting long-acting monthly and weekly formulations, as well as oral medications [2] - The company has established strategic partnerships with firms such as Borui Biopharmaceuticals and Shenzhen Carbon Cloud Smart Peptide Drug Technology Co., Ltd. to provide integrated pharmaceutical services through its CRDMO business [2] - The company leverages its deep technical reserves in the peptide field to enhance its research, development, production, and quality management capabilities [2]